Mutations in inhibin and activin genes associated with human disease

Molecular and Cellular Endocrinology

Volumn 359, Issue 1-2, 2012, Pages 113-120

  Shelling, Andrew N ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Activin; Genetic disease; Inhibin; Ovarian cancer; Premature ovarian failure

Indexed keywords

ACTIVIN; FOLLITROPIN; INHIBIN; INHIBIN ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADRENAL TUMOR; DNA POLYMORPHISM; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENITAL TRACT CANCER; GERM CELL TUMOR; HORMONE RELEASE; HUMAN; MULTIPLE PREGNANCY; NONHUMAN; OVARY INSUFFICIENCY; PHENOTYPE; PREECLAMPSIA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TWIN PREGNANCY;

ACTIVINS; ANIMALS; ENDOCRINE GLAND NEOPLASMS; FEMALE; GENITAL NEOPLASMS, MALE; HUMANS; INHIBINS; MALE; MUTATION; PRE-ECLAMPSIA; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; SIGNAL TRANSDUCTION; TGF-BETA SUPERFAMILY PROTEINS; TWINS, DIZYGOTIC;

EID: 84861663369     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.07.031     Document Type: Review

References (70)

1. Akutsu K., et al. Phenotypic heterogeneity of Marfan-like connective tissue disorders associated with mutations in the transforming growth factor-beta receptor genes. Circ. J. 2007, 71:1305-1309.
2. Balanathan P., et al. Epigenetic regulation of inhibin α-subunit gene in prostate cancer cell lines. J. Mol. Endocrinol. 2004, 32:55-67.
3. Barton D.E., et al. Mapping of genes for inhibin subunits alpha, beta A, and beta B on human and mouse chromosomes and studies of jsd mice. Genomics 1989, 5:91-99.
4. Bilandzic M., Stenvers K.L. Betaglycan: a multifunctional accessory. Mol. Cell. Endrocrinol. 2011, 339(1-2):180-189.
5. Bernard D.J., Chapman S.C., Woodruff T.K. Mechanisms of inhibin signal transduction. Recent Prog. Horm. Res. 2001, 56:417-450.
6. Burger H.G., Fuller P.J. The inhibin/activin family and ovarian cancer. Trends Endocrinol. Metab. 1996, 7(6):197-202.
7. Chand A.L., et al. Mutational analysis of GDF9 and BMP15 as candidate genes in premature ovarian failure. Fertil. Steril. 2006, 86(4):1009-1012.
8. Chand A.L., et al. Functional analysis of the human inhibin A257T mutation and its potential role in premature ovarian failure. Hum. Reprod. 2007, 22(12):3241-3248.
9. Chand A.L., Harrison C.A., Shelling A.N. Inhibin and premature ovarian failure. Mol. Hum. Reprod. 2010, 16(1):39-50.
10. Ciarmela P., et al. Mutational analysis of the inhibin alpha gene in preeclamptic women. J. Endocrinol. Invest. 2005, 28:30-33.
11. Corre T., et al. A large-scale association study to assess the impact of known variants of the human INHA gene on premature ovarian failure. Hum. Reprod. 2009, 24(8):2023-2028.
12. Coulam C.B., Adamson S.C., Annegers J.F. Incidence of premature ovarian failure. Obstet. Gynecol. 1986, 67:604-606.
13. de Caestecker M.P., Piek E., Roberts A.B. Role of transforming growth factor-beta signaling in cancer. J. Natl. Cancer Inst. 2000, 92(17):1388-1402.
14. Depasquale S., et al. Molecular analysis of inhibin A and activin A subunit gene loci in epithelial ovarian cancer. Int. J. Gynecol. Cancer 2002, 12:443-447.
15. Di Pasquale E., Beck-Peccoz P., Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am. J. Hum. Genet. 2004, 75(1):106-111.
16. Dixit H., Deendayal M., Singh L. Mutational analysis of the mature peptide region of inhibin genes in Indian women with ovarian failure. Hum. Reprod. 2004, 19:1760-1764.
17. Dixit H., et al. Expansion of the germline analysis for the INHA gene in Indian women with ovarian failure. Hum. Reprod. 2006, 21:1643-1644.
18. Findlay J.K., et al. Recruitment and development of the follicle; the roles of the transforming growth factor-beta superfamily. Mol. Cell. Endocrinol. 2002, 191(1):35-43.
19. Francis-Thickpenny K.M., et al. Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma. Br. J. Cancer 2001, 85(5):687-691.
20. Frazer K.A., et al. Human genetic variation and its contribution to complex traits. Nat. Rev. Genet. 2009, 10:241-251.
21. Fuller P.J., Chu S. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol. Metab. 2004, 15(3):122-128.
22. Gatza C.E., Oh S.Y., Blobe G.C. Roles for the type III TGF-beta receptor in human cancer. Cell. Signal. 2010, 22:1163-1174.
23. Gold E., et al. Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo. Am. J. Pathol. 2009, 174(1):184-195.
24. Gordon K.J., Blobe G.C. Role of the transforming factor-β superfamily signaling pathways in human disease. Biochim. Biophys. Acta 2008, 1782:197-228.
25. Harradine K.A., Akhurst R.J. Mutations of TGFβ signaling molecules in human disease. Ann. Med. 2006, 38(6):403-414.
26. Harris S.E., et al. INHA promoter polymorphisms are associated with premature ovarian failure. Mol. Hum. Reprod. 2005, 11:779-784.
27. Healy D.L., et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N. Eng. J. Med. 1993, 329:1539-1542.
28. Howe J.R., et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J. Med. Genet. 2004, 41:484-491.
29. Ikushima H., Miyazono K. TGFβ signalling: a complex web in cancer progression. Nat. Rev. Cancer 2010, 10:415-424.
30. Imbeaud S., et al. Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor. Nat. Genet. 1995, 11:382-388.
31. Jeong H.J., et al. G769A variation of inhibin alpha-gene in Korean women with premature ovarian failure. Yonsei Med. J. 2004, 45:479-482.
32. Kalkhoven E., et al. Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ. 1995, 6:1151-1161.
33. Knight P.G., Glister C. TGF-β superfamily members and ovarian follicle development. Reproduction 2006, 132:191-206.
34. Lau A.L., et al. Activin betaC and betaE genes are not essential for mouse liver growth, differentiation, and regeneration. Mol. Cell. Biol. 2000, 20(16):6127-6137.
35. Lewis K.A., et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 2000, 404:411-414.
36. Longui C.A., et al. Inhibin α-subunit (INHA) gene and locus changes in paediatic adrenocortical tumours from TP53 T337H mutation heterozygote carriers. J. Med. Genet. 2004, 41:354-359.
37. Luisi L., et al. Expression and secretion of activin A: possible physiological and clinical implications. Eur. J. Endocrinol. 2001, 145:225-236.
38. L'vshits G.B., et al. Use of forms of DNA analysis for diagnosis of heteditary forms of premature ovarian failure. Cytol. Genet. 2005, 39(2):59-63.
39. MacNaughton J., et al. Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clin. Endocrinol. 1992, 36:339-345.
40. Matzuk M.M., et al. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992, 360:313-319.
41. Matzuk M.M., et al. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc. Natl. Acad. Sci. USA 1994, 91:8817-8821.
42. Marozzi A., et al. Mutation analysis of the inhibin alpha gene in a cohort of Italian women affected by ovarian failure. Hum. Reprod. 2002, 17:1741-1745.
43. Medan M.S., et al. Immunization against endogenous inhibin increases normal oocyte/embryo production in adult mice. Endocrine 2004, 24(2):115-119.
44. Mellor S.L., et al. Loss of the expression and localization of inhibin alpha-subunit in high grade prostate cancer. J. Clin. Endocrinol. Metab. 1998, 83(3):969-975.
45. Montgomery G.W., et al. Dizygotic twinning is not linked to variation at the alpha-inhibin locus on human chromosome 2. J. Clin. Endocrinol. Metab. 2000, 85:3391-3395.
46. Moss T.J., Wallrath L.L. Connections between epigenetic gene silencing and human disease. Mutat. Res. 2007, 618(1-2):163-174.
47. Munz W., et al. Serum inhibin A, inhibin B, pro-alphaC, and activin A levels in women with idiopathic premature ovarian failure. Fertil. Steril. 2004, 82(3):760-762.
48. Myers M., et al. Loss of inhibin alpha uncouples oocyte-granulosa cell dynamics and disrupts postnatal folliculogenesis. Dev. Biol. 2009, 334(2):458-467.
49. Nicoloso M.S., et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010, 70(7):2789-2798.
50. Pelkey T.J., et al. The alpha subunit of inhibin in adrenal cortical neoplasia. Mod. Pathol. 1998, 11(6):516-524.
51. Persani L., Rossetti R., Cacciatore C. Genes involved in human premature ovarian failure. J. Mol. Endocrin. 2010, 45:257-279.
52. Prakash G.J., et al. Mutational analysis of inhibin alpha gene revealed three novel variations in Indian women with premature ovarian failure. Fertil. Steril. 2010, 94(1):90-98.
53. Purdue M.P., et al. Genetic variation in the inhibin pathway and risk of testicular germ cell tumors. Cancer Res. 2008, 68(8):3043-3048.
54. Ramachandran A., et al. Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett. 2009, 285(2):157-165.
55. Richardson S.J., et al. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J. Clin. Endocrinol. Metab. 1987, 65:1231-1237.
56. Risbridger G.P., et al. Activins and inhibins in endocrine and other tumors. Endocr. Rev. 2001, 22(6):836-858.
57. Robertson D.M. Combined inhibin and CA125 assays in the detection of ovarian cancer. Clin. Chem. 1999, 45(5):651-658.
58. Robertson D.M. Inhibins/activins as diagnostic markers for ovarian cancer. Mol. Cell. Endocrinol. 2002, 191:97-103.
59. Shelling A.N., et al. Inhibin: a candidate gene for premature ovarian failure. Hum. Reprod. 2000, 15(2):2644-2649.
60. Shelling A.N., Ferguson L.R. Genetic variation in human disease, and a new role for copy number variants. Mutat. Res. 2007, 622:33-41.
61. Shelling A.N. Progress in the study of genetic disease: bringing new light to complex problems. Postgrad. Med. J. 2009, 85(1008):505-507.
62. Shelling A.N. Premature ovarian failure. Reproduction 2010, 140(5):633-641.
63. Stenvers K.L., Findlay J.K. Inhibins: from reproductive hormones to tumor suppressors. Trends Endocrinol. Metab. 2009, 21(3):174-180.
64. Sundblad V., et al. Controversial role of inhibin alpha-subunit gene in the aetiology of premature ovarian failure. Hum. Reprod. 2006, 21:1154-1160.
65. Takebayashi K., et al. Mutation analysis of the growth differentiation factor-9 and -9B genes in patients with premature ovarian failure and polycystic ovary syndrome. Fertil. Steril. 2000, 74(5):976-979.
66. Te Velde E.R., Pearson P.L. The variability of female reproductive ageing. Hum. Reprod. Update 2002, 8(2):141-154.
67. Watson R.H., et al. Loss of heterozygosity at the α-inhibin locus on chromosome 2q is not a feature of human granulosa cell tumors. Gynecol. Oncol. 1997, 65:387-390.
68. Woad K.J., et al. Investigating the association between inhibin alpha gene promoter polymorphisms and premature ovarian failure. Fertil. Steril. 2008, 91(1):62-66.
69. Zhou X., et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.
70. Zintzaras E. Inhibin alpha gene and susceptibility to premature ovarian failure: a data synthesis. Mol. Hum. Reprod. 2010, 15(9):551-555.